Results 1 to 10 of about 31,793 (243)
Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease [PDF]
New England Journal of Medicine, 2017 International ...
William R Hiatt +2 more
exaly +5 more sources
The effect of antiplatelet drug on coronary endothelial and microvascular function: comparison with ticagrelor and clopidogrel [PDF]
The Korean Journal of Internal Medicine, 2021 Background/Aims Coronary endothelial and microvascular function play important roles in cardiovascular disease. We aimed to evaluate the effect of ticagrelor on coronary artery function and tested the antiplatelet effect of low dose ticagrelor in East ...
Woong Gil Choi +4 more
doaj +1 more source
Frontiers in Pharmacology, 2021 Ticagrelor is the first reversibly binding, direct-acting, oral P2Y12 receptor inhibitor. The contribution of UDP-glucuronosyltransferases (UGTs) enzymes to the metabolism of ticagrelor to its glucuronide conjugation, ticagrelor-O-glucuronide, in human ...
Shuaibing Liu +6 more
doaj +1 more source
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021 Background We aimed to evaluate the age‐dependent effect of ticagrelor monotherapy after 3‐month dual‐antiplatelet therapy (DAPT) versus ticagrelor‐based 12‐month DAPT on major bleeding and cardiovascular events in patients with acute coronary syndrome ...
Byung Gyu Kim +10 more
doaj +1 more source
Hospital‐Level Variation in Ticagrelor Use in Patients With Acute Coronary Syndrome
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022 Background Despite improved outcomes associated with ticagrelor compared with clopidogrel in acute coronary syndrome (ACS), many studies have demonstrated slow adoption of ticagrelor in the United States because of its increased cost. Less is known about
Aya F. Ozaki +6 more
doaj +1 more source
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023 Background Effectiveness estimates from observational studies on ticagrelor use in routine clinical care are conflicting, with some contrary to the results of the pivotal randomized controlled trial of ticagrelor in acute coronary syndrome.
Kasper Johannesen +5 more
doaj +1 more source
Frontiers in Cardiovascular Medicine, 2022 PurposePrevious trials have demonstrated that ticagrelor was superior to clopidogrel in acute coronary syndrome (ACS) patients. However, several recent studies showed that ticagrelor was associated with a significantly higher risk of bleeding compared ...
Wenxing Peng +3 more
doaj +1 more source
The effect of ticagrelor on ischemia-reperfusion injury of kidney: is the pleiotropic effect a valid factor? [PDF]
Kafkas Universitesi Veteriner Fakültesi Dergisi, 2017 Bu çalışmada, ticagrelor"un ratların böbreğinde oluşturulan iskemi-reperfüzyon hasarına karşı koruyucu etkisinin histolojik, biyokimyasal ve immünohistokimyasal yöntemler kullanılarak tanımlanması amaçlanmıştır.
Murat BAĞCIOĞLU +3 more
doaj +1 more source
Stabilizing role of platelet P2Y(12) receptors in shear-dependent thrombus formation on ruptured plaques [PDF]
, 2010 Background: In most models of experimental thrombosis, healthy blood vessels are damaged. This results in the formation of a platelet thrombus that is stabilized by ADP signaling via P2Y(12) receptors.
J. J. J. van Giezen +9 more
core +13 more sources
Comparison of bioavailability and antiplatelet action of ticagrelor in patients with ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: A prospective, observational, single-centre study. [PDF]
PLoS ONE, 2017 Data from available studies suggest that the presence of ST-elevation myocardial infarction (STEMI) may be associated with delayed and attenuated ticagrelor bioavailability and effect compared with non-ST-elevation myocardial infarction (NSTEMI).In a ...
Piotr Adamski +16 more
doaj +1 more source